SARS-CoV-2 antibody determination in a vaccinated and recovered cohort in Austria

Elisabeth Mara; Tobias Mader; Johannes Gratzer; Stefanie Hochegger; Thomas Pekar

doi:10.1016/j.clicom.2022.08.001

SARS-CoV-2 antibody determination in a vaccinated and recovered cohort in Austria

Elisabeth Mara
, Tobias Mader
, Johannes Gratzer
, Stefanie Hochegger
, Thomas Pekar

University of Applied Sciences Wiener Neustadt

Research output: Contribution to journal › Article

Abstract

Since December 2019 the world has been dealing with a severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic. The first SARS-CoV-2 vaccine was made available in Europe at the end of 2020. 202 volunteers from the vicinity of the University of Applied Sciences Wiener Neustadt took part in this study; their IgG levels recognizing the RBD of SARS-CoV-2 were determined. The aim was to evaluate the SARS-CoV-2 titer levels of vaccinated, recovered and vaccinated plus recovered persons. We could show that there is a significant difference in the antibody levels of vaccinated, vaccinated plus recovered and only recovered probands. Additionally, the highest antibody levels were found in triple vaccinated persons. Furthermore, the Moderna vaccine seems to have a higher immune response.

Original language	English
Pages (from-to)	136-141
Number of pages	6
Journal	Clinical Immunology Communications
Volume	2
DOIs	https://doi.org/10.1016/j.clicom.2022.08.001
Publication status	Published - Dec 2022

Access to Document

10.1016/j.clicom.2022.08.001

Cite this

@article{064f3afe038b425c9266256bbc91f30d,

title = "SARS-CoV-2 antibody determination in a vaccinated and recovered cohort in Austria",

abstract = "Since December 2019 the world has been dealing with a severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic. The first SARS-CoV-2 vaccine was made available in Europe at the end of 2020. 202 volunteers from the vicinity of the University of Applied Sciences Wiener Neustadt took part in this study; their IgG levels recognizing the RBD of SARS-CoV-2 were determined. The aim was to evaluate the SARS-CoV-2 titer levels of vaccinated, recovered and vaccinated plus recovered persons. We could show that there is a significant difference in the antibody levels of vaccinated, vaccinated plus recovered and only recovered probands. Additionally, the highest antibody levels were found in triple vaccinated persons. Furthermore, the Moderna vaccine seems to have a higher immune response.",

author = "Elisabeth Mara and Tobias Mader and Johannes Gratzer and Stefanie Hochegger and Thomas Pekar",

note = "{\textcopyright} 2022 Published by Elsevier Inc.",

year = "2022",

month = dec,

doi = "10.1016/j.clicom.2022.08.001",

language = "English",

volume = "2",

pages = "136--141",

journal = "Clinical Immunology Communications",

issn = "2772-6134",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - SARS-CoV-2 antibody determination in a vaccinated and recovered cohort in Austria

AU - Mara, Elisabeth

AU - Mader, Tobias

AU - Gratzer, Johannes

AU - Hochegger, Stefanie

AU - Pekar, Thomas

PY - 2022/12

Y1 - 2022/12

N2 - Since December 2019 the world has been dealing with a severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic. The first SARS-CoV-2 vaccine was made available in Europe at the end of 2020. 202 volunteers from the vicinity of the University of Applied Sciences Wiener Neustadt took part in this study; their IgG levels recognizing the RBD of SARS-CoV-2 were determined. The aim was to evaluate the SARS-CoV-2 titer levels of vaccinated, recovered and vaccinated plus recovered persons. We could show that there is a significant difference in the antibody levels of vaccinated, vaccinated plus recovered and only recovered probands. Additionally, the highest antibody levels were found in triple vaccinated persons. Furthermore, the Moderna vaccine seems to have a higher immune response.

AB - Since December 2019 the world has been dealing with a severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic. The first SARS-CoV-2 vaccine was made available in Europe at the end of 2020. 202 volunteers from the vicinity of the University of Applied Sciences Wiener Neustadt took part in this study; their IgG levels recognizing the RBD of SARS-CoV-2 were determined. The aim was to evaluate the SARS-CoV-2 titer levels of vaccinated, recovered and vaccinated plus recovered persons. We could show that there is a significant difference in the antibody levels of vaccinated, vaccinated plus recovered and only recovered probands. Additionally, the highest antibody levels were found in triple vaccinated persons. Furthermore, the Moderna vaccine seems to have a higher immune response.

U2 - 10.1016/j.clicom.2022.08.001

DO - 10.1016/j.clicom.2022.08.001

M3 - Article

C2 - 38013972

SN - 2772-6134

VL - 2

SP - 136

EP - 141

JO - Clinical Immunology Communications

JF - Clinical Immunology Communications

ER -

SARS-CoV-2 antibody determination in a vaccinated and recovered cohort in Austria

Abstract

Access to Document

Fingerprint

Cite this